Abbott Laboratories
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Abbott Laboratories's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $99 of operating cash. Lower than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$99Over the last 3 years, every $100 of reported profit came with $99 of operating cash.
Lower than 85% of Healthcare companies in United States.
Self-Funding Ratio
3.9×Over the last 3 years its own operating cash covered its investment spending (capex) 3.9 times.
Higher than 82% of Healthcare companies in United States.
Cash Locked Ratio
$24For every $100 of sales, $24 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $20 tied up three years earlier.
More money tied up than 50% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales barely changed
Sales changed by +2% in 3 years, too little to measure extra profit per extra sales.
Asset Productivity Ratio
+2% / +16%In 3 years sales changed by +2% while total assets changed by +16%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
3.2×Debt due within a year is covered 3.2 times by its yearly operating cash.
Higher than 77% of Healthcare companies in United States.
Cash Cushion Ratio
−3%Debt, after subtracting cash, equals 3% of its market value (net debt).
Lower than 72% of Healthcare companies in United States.
Tangible Assets Ratio
66%Of every $100 the company owns, $66 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
Less tangible than 65% of Healthcare companies in United States.
Tangible Net Worth Ratio
43%Of every $100 of net worth, $43 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Less tangible than 56% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
Abbott Laboratories owes $0.52 for every $1 it owns. Net profit fell 51% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
38.1Investors pay $38.1 for every $1 of Abbott Laboratories' yearly profit, higher than 69% of Healthcare companies in United States.
P/B ratio
3.41The share price is 3.41 times Abbott Laboratories' book value per share, higher than 60% of Healthcare companies in United States.
Market cap
$177.4 BThe total market value of all of Abbott Laboratories' shares at today's price (share price × number of shares), larger than almost all Healthcare companies in United States. PosiCap size class: Tito Cap.
Net worth (book value)
$52.1 BWhat Abbott Laboratories would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (31 Mar 2026).
Book value per share
$30.09Net worth divided by the number of shares. The share price of $102.51 is 3.4 times this, which is the P/B above.
Owes vs Owns
0.52×Abbott Laboratories owes $0.52 for every $1 it owns (moderate), higher than 58% of Healthcare companies in United States.
Dividend yield
2.51%Abbott Laboratories pays 2.51% of its share price as dividends a year, higher than 85% of dividend-paying Healthcare companies in United States.
Revenue growth
+6%Revenue rose 6% in the year to Dec 2025, and grew 1% a year on average over 3 years.
Profit growth
-51%Net profit fell 51% in the year to Dec 2025, and shrank 2% a year on average over 3 years.
Profit margin
14.7%Abbott Laboratories keeps $15 of every $100 of revenue as net profit.
Cash quality
1.5×Cash from Abbott Laboratories' business was 1.5× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
16.3×Abbott Laboratories' operating profit covered its interest costs 16.3 times in the year to Dec 2025.
Cash vs debt
Net debtAbbott Laboratories had $4.9 B more debt than cash (net debt) at Dec 2025.
Questions
What is Abbott Laboratories' P/E ratio?
Investors pay $38.1 for every $1 of Abbott Laboratories' yearly profit, higher than 69% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Abbott Laboratories: $177.4 B ÷ $52.1 B (31 Mar 2026) = 3.4.
How much does Abbott Laboratories owe compared with what it owns?
Abbott Laboratories owes $0.52 for every $1 it owns (moderate), higher than 58% of Healthcare companies in United States.
Does Abbott Laboratories pay a dividend?
Yes. Abbott Laboratories pays 2.51% of its share price as dividends a year, higher than 85% of dividend-paying Healthcare companies in United States.
Is Abbott Laboratories' revenue growing?
Revenue rose 6% in the year to Dec 2025, and grew 1% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.